Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients
NCT07539038
Summary
The advances in early detection coupled with improvements in treatments have led to an ever-increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may represent valid additions to the currently available treatment options. Interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, improve survival and the quality of life. This is an observational, prospective study aimed at evaluating the effects of physical activity on the quality of life of patients with early stage hormone receptor positive breast cancer receiving adjuvant hormonal therapy and adhering to a physical activity program lasting for a total of 12 weeks organized by ANDOS onlus (Associazione Italiana Donne Operate al Seno).
Eligibility
Inclusion Criteria: * Patients with early stage (I-IIIa) hormone receptor-positive breast cancer receiving adjuvant endocrine therapy * Female patients ≥18 years of age * Written informed consent must be obtained before any study-related assessment is performed * Participation to the Medicina and Sport physical activity program organized by Andos Pordenone Exclusion Criteria: * Patients with early hormone receptor negative breast cancer * Patients with early hormone receptor positive breast cancer receiving chemotherapy * Patients with advanced/metastatic breast cancer. * Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias). * Patients with history of vertebral and/or femoral fractures * Patients with CVDs not optimally controlled by medical therapy
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07539038